Treatment of tuberculosis in South Kazakhstan: clinical and economical aspects
- PMID: 24375246
Treatment of tuberculosis in South Kazakhstan: clinical and economical aspects
Abstract
Background and objective: Since 1990, the tuberculosis incidence rate in Eastern Europe and post-Soviet republics has been increasing in many countries including Kazakhstan. This problem is particularly important in Kazakhstan regions with limited financial resources, among them - in South Kazakhstan province. The aim of this study was to investigate the main clinical and antibiotic-related economic aspects of tuberculosis treatment in South Kazakhstan province.
Material and methods: In total, 502 patients participated in the study. They were hospitalized to the tuberculosis dispensary of Sayram district (South Kazakhstan province) in 2007-2013. Statistical analysis included logistic regression for better treatment outcomes and analysis of antibiotic treatment costs.
Results: Two-thirds of patients had infiltrative tuberculosis (67%). Positive treatment outcomes were determined in 85% of cases. The patients were mostly treated with cycloserine, protionamide, capreomycin, and ofloxacin. The majority of antibiotic costs were related to the treatment with capreomycin. In case of the positive results of the test for Mycobacterium tuberculosis, antibiotic expenses were almost 3 times greater than in case of negative test results (P<0.001).
Conclusions: The majority of patients had extensively drug-resistant tuberculosis. The negative results of the test for Mycobacterium tuberculosis at discharge were not related to pretreatment factors. Antibiotic-related costs were significantly higher in case of the positive results of the test of Mycobacterium tuberculosis, but were not associated with gender, residence place, hospitalization recurrence, or main blood test results before treatment.
Similar articles
-
The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.BMC Infect Dis. 2016 Sep 5;16(1):470. doi: 10.1186/s12879-016-1802-x. BMC Infect Dis. 2016. PMID: 27595779 Free PMC article.
-
Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.Microb Drug Resist. 2010 Mar;16(1):81-6. doi: 10.1089/mdr.2009.0073. Microb Drug Resist. 2010. PMID: 20192820
-
Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.Int J Tuberc Lung Dis. 2012 Dec;16(12):1588-93. doi: 10.5588/ijtld.12.0322. Epub 2012 Oct 2. Int J Tuberc Lung Dis. 2012. PMID: 23032215
-
Molecular snapshot of Mycobacterium tuberculosis population in Kazakhstan: a country-wide study.Tuberculosis (Edinb). 2015 Sep;95(5):538-46. doi: 10.1016/j.tube.2015.04.012. Epub 2015 May 14. Tuberculosis (Edinb). 2015. PMID: 26076582
-
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.Lancet Infect Dis. 2010 Sep;10(9):621-9. doi: 10.1016/S1473-3099(10)70139-0. Lancet Infect Dis. 2010. PMID: 20797644 Review.
Cited by
-
A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.Pharmacoeconomics. 2020 Aug;38(8):819-837. doi: 10.1007/s40273-020-00910-w. Pharmacoeconomics. 2020. PMID: 32363543 Free PMC article.
-
Linezolid for drug-resistant pulmonary tuberculosis.Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD012836. doi: 10.1002/14651858.CD012836.pub2. Cochrane Database Syst Rev. 2019. PMID: 30893466 Free PMC article.
-
Epidemiology of tuberculosis in Kazakhstan: data from the Unified National Electronic Healthcare System 2014-2019.BMJ Open. 2023 Oct 11;13(10):e074208. doi: 10.1136/bmjopen-2023-074208. BMJ Open. 2023. PMID: 37821138 Free PMC article.
-
Map the gap: missing children with drug-resistant tuberculosis.Public Health Action. 2015 Mar 21;5(1):45-58. doi: 10.5588/pha.14.0100. Public Health Action. 2015. PMID: 26400601 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical